U.S. PATENT AND TRADEMARK OFFICE

Applicant:

AZUMA et al.

Conf.:

7730

OCT 2 9 2001

Appl. No.:

09/743,750

Group:

1643

Filed:

January 16, 2001

Examiner: UNASSIGNED

TECH CENTER 1600/2901

For:

FORMULATIONS USEFUL FOR IMMUNOTHERAPY

FOR CANCERS CONTAINING BACTERIAL COMPONENT AS AN ACTIVE INGREDIENT

### REQUEST FOR A CORRECTED OFFICIAL FILING RECEIPT

9/26/01 Assistant Commissioner for Patents

Sir:

with

Attached hereto is the Official Filing Receipt in connection with the above-identified application.

### THE FOLLOWING CORRECTION(S) IS/ARE RESPECTFULLY REQUESTED: FILING DATE:

Please replace "03/26/2001"

--01/16/2001--

Washington, DC 20231

is respectfully requested that the U.S. Trademark Office forward/issue a new Filing Receipt with the correction(s) indicated above. Support for the correction(s) is readily apparent on the enclosed photocopy of the stamped postcard showing the correct filing date.

RECEIVED

OCT 2 3 2001

OFFICE OF PETITIONS

The correction(s) is/are due to error by the U.S. Patent and Trademark Office; therefore no fee is due.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

John W. Bailey, #32,881

P.O. Box 747

Falls Church, VA 22040-0747

(703) 205-8000

Attachment

JWB/end

(Rev.03/19/01)

## **RECEIVED**

OCT 2 9 2001

TECH CENTER 1600/2900

25=(1=25	
PCT/JP99/03837 77	PCT/JP99/03837
Papers Filed herewith on:	Papers Filed herewith on: 1-16-01
DOCKET NO .: 20-48028	DOCKET NO.: 20-48028
ATTY: JWB	ATTY:: JUB
APPLICANT(S): I. AZUMA et al.	APPLICANT(S): T AZUMA etal.
USSN: NEW FILED: 1-16-01	USSN: NEW FILED: 1-16-01
PAT NO.:	PAT NO.:
New Application with Transmittal Letter	New Application with Transmittal Letter,
☐ Utility ☐ Design ☐ CIP 🔀 PCT ☐ Provisional	Utility Design DCIP MOPCT Provisional
☐ Filing Under 37 CFR 1.53(b) ☐ CONT ☐ DIV	☐ Filing Under 37 CFR 1.53(b) ☐ CONT ☐ DIV
Filing Under 37 CFR 1.53(d) (CPA)	
Specification Consisting of: 49 pages \$	Specification Consisting of: 49 pages
Filing Under 37 CFR 1.53(d) (CPA)  Specification Consisting of:	☐ Filing Under 37 CFR 1.53(d) (CPA) ☐ Specification Consisting of: 49 pages ☐ Combined Declaration & Power of Attorney ☐ Assignment / Cover Latter, 00 7 1, 7 7 5 0
☐ Assignment / Cover Letter	Assignment / Cover Letter 09/743750
Letter to Official Draftsman	Letter to Official Draftsman
☑Drawings ② Sheets ☑Formal ☐ Informal ☐ Red-Ink	☐ Drawings ☐ Sheets ☐ Formal ☐ Informal ☐ Red-Ink
Completion of Filing Requirements, PCT/DO/EO/905	Completion of Filing Requirements, PCT/DO/EO/905
or PTO-1533 and Executed Declaration	or PTO-1533 and Executed Declaration
Priority Document(s) / Cover Letter, No. Doc.	☐ Priority Document(s) / Cover Letter, No. Doc.
FAmendment: Preliminary	Priority Document(s) / Cover Letter, No. Doc.  Pamendment: Reclination  Transmitted Transm
☐ Transmtl Ltr ☐ Large Entity ☐ Small Entity	☐ Transmtl Ltr ☐ Large Entity ☐ Small Entity
Response   AN 1 6 2001	☐ Response
Information Disci Stmnt. PTO-1449(s)ref(s)	Prinformation Disci Stmnt. PTO-1449(s) ref(s)
□ Notice of Appeal □ App Brief	☐ Notice of Appeal ☐ Appeal Brief
Issue Fee Transmittal	☐ Issue Fee Transmittal
FEES: \$1,626.00 \$ 68100	OFFEES: \$1.626.00 \$ 6017369
Letter:	Letter:
Fother: Form PCTIPEAL409:	Bother: FOYM IPEA/409.
Euglish trans1. of Art. 34 claims	Euclish transl, of Art. 34
JPO Slarch Report	Claims, PTO-1449, JPO Seas (4)
Receipt is hereby acknowledged of the papers filed as indicated in connection with the above identified case.	Receipt is hereby acknowledged of the papers filed as
COMMISSIONER OF PATENTS AND TRADEMARKS	indicated in connection with the above identified case. COMMISSIONER OF PATENTS AND TRADEMARKS
Due Date:1 ~ [ 6 ~ 6 ]	Due Date: 1-114=QL
Handcarry:	1522-Rock PCT/PID 1 6 JAN 2001
503414	3014
	30741

**RECEIVED** 

OCT 2 3 2001

**OFFICE OF PETITIONS** 



### United States Patent and Trademark Offici

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023

німстом, D.C. 20231 www.uspta.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/743.750	03/26/2001	1643	1626	0020-4802P	8	26	22

SEP 2 6 2001

**CONFIRMATION NO. 7730** 

2292 BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040-0747 FILING RECEIPT

'OC0000000006533193'

Date Mailed: 09/07/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Ichiro Azuma, Sapporo-shi, JAPAN; Norio Hamamatsu, Kawanishi-shi, JAPAN; Toshio Fujinaga, Ibaraki-shi, JAPAN;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/JP99/03837 07/16/1999

Foreign Applications

JAPAN 202366/1998 07/16/1998 JAPAN 236148/1998 08/21/1998 JAPAN 236163/1998 08/21/1998 JAPAN 236164/1998 08/21/1998

RECEIVED

OCT 2 3 2001

Projected Publication Date: N/A

OFFICE OF PETITIONS

Non-Publication Request: No

Early Publication Request: No

Title



ingredient Preparations for immunotherapy for cancer having bacterial somatic constituent as the active

Preliminary Class

432

Date: 09/07/2001

Data entry by: NGUYEN, SON Team: OIPE

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Cod of Federal R gulati ns, 5.11 & 5.15

### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

#### PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231

....